Jie Mei
Department of Neurology and Department of Experimental Neurology, Neurocure Cluster of Excellence, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
Stefanie Banneke
German Federal Institute for Risk Assessment, German Center for the Protection of Laboratory Animals (Bf3R), Berlin, Germany
Janet Lips
Department of Neurology and Department of Experimental Neurology, Neurocure Cluster of Excellence, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; QUEST – Center for Transforming Biomedical Research, Berlin Institute of Health (BIH); Center for Stroke Research, Charité - Universitätsmedizin Berlin, Berlin, Germany
Melanie T. C. Kuffner
Department of Neurology and Department of Experimental Neurology, Neurocure Cluster of Excellence, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Center for Stroke Research, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin-Brandenburg School for Regenerative Therapies (BSRT), Berlin, Germany
Christian J. Hoffmann
Department of Neurology and Department of Experimental Neurology, Neurocure Cluster of Excellence, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Center for Stroke Research, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health (BIH), Berlin, Germany
Ulrich Dirnagl
Department of Neurology and Department of Experimental Neurology, Neurocure Cluster of Excellence, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; QUEST – Center for Transforming Biomedical Research, Berlin Institute of Health (BIH); Center for Stroke Research, Charité - Universitätsmedizin Berlin, Berlin, Germany; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany; German Center for Cardiovascular Research (DZHK), Berlin, Germany
Matthias Endres
Department of Neurology and Department of Experimental Neurology, Neurocure Cluster of Excellence, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Center for Stroke Research, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health (BIH), Berlin, Germany; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany; German Center for Cardiovascular Research (DZHK), Berlin, Germany
Christoph Harms
Department of Neurology and Department of Experimental Neurology, Neurocure Cluster of Excellence, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; QUEST – Center for Transforming Biomedical Research, Berlin Institute of Health (BIH); Center for Stroke Research, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health (BIH), Berlin, Germany
Julius V. Emmrich
Department of Neurology and Department of Experimental Neurology, Neurocure Cluster of Excellence, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; German Federal Institute for Risk Assessment, German Center for the Protection of Laboratory Animals (Bf3R), Berlin, Germany; Berlin Institute of Health (BIH), Berlin, Germany
[hide affiliations]
Abstract
Ideally, humane endpoints allow early termination of experiments by minimizing an animal’s discomfort, distress and pain while ensuring that scientific objectives are reached. Yet, lack of commonly agreed methodology and heterogeneity of cut-off values published in the literature remain a challenge to the accurate determination and application of humane endpoints.
With the aim to synthesize and appraise existing humane endpoint definitions for commonly used physiological parameters, we conducted a systematic review of mouse studies of acute and chronic disease models that used body weight, temperature and/or sickness scores for endpoint definition. We searched for studies in two electronic databases (MEDLINE/Pubmed and Embase). Out of 110 retrieved full-text manuscripts, 34 studies were included. We found large intra- and inter-model variance in humane endpoint determination and application due to varying animal models, lack of standardized experimental protocols, and heterogeneity of performance metrics (part 1).
We then used previously published and unpublished data on weight, temperature, and sickness scores from mouse models of sepsis and stroke and applied machine learning models to assess the usefulness of this method for parameter selection and endpoint definition across models. Machine learning models trained with physiological data and sickness severity score or modified DeSimoni neuroscore identified animals with a high risk of death at an early time point in both mouse models of stroke (male: 93.2% at 72 h post-treatment; female: 93.0% at 48 h post-treatment) and sepsis (96.2% at 24 h post-treatment), thus demonstrating generalizability of endpoint determination across models (part 2).
